NKGen Biotech, Inc. Common Stock
Other OTCTotal Valuation
NKGen Biotech, Inc. Common Stock carries a market capitalization of 7.84M, placing it among publicly traded companies globally. Its enterprise value stands at 40.21M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.84M |
| Enterprise Value | 40.21M |
Share Statistics
NKGen Biotech, Inc. Common Stock currently has 35.72M shares outstanding.
| Shares Outstanding | 35.72M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | -0.20 |
| P/FCF Ratio | -0.53 |
| P/OCF Ratio | -0.45 |
Financial Position
NKGen Biotech, Inc. Common Stock maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -65.33, indicating conservative leverage, while an interest coverage ratio of -11.43 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.02 |
| Quick Ratio | 0.00 |
| Debt / Equity | -65.33 |
| Debt / EBITDA | -1.02 |
| Interest Coverage | -11.43 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -241.23 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 31.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 7,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
NKGen Biotech, Inc. Common Stock's stock has declined approximately -84% over the past 52 weeks. The 50-day moving average sits at 0.05, while the 200-day moving average is 0.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | -84% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.13 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -30.01M, while operating income came in at -31.30M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -31.30M |
| Pretax Income | -48.47M |
| Net Income | -48.48M |
| EBITDA | -30.01M |
| EBIT | -31.30M |
| Earnings Per Share (EPS) | -1.66 |
Balance Sheet
NKGen Biotech, Inc. Common Stock holds 8,000.00 in cash and equivalents against 30.74M in total debt, resulting in a net debt position of 30.30M. Total book value stands at -177.00M, with working capital of -36.21M providing operational flexibility.
| Cash & Cash Equivalents | 8,000.00 |
| Total Debt | 30.74M |
| Net Debt | 30.30M |
| Equity (Book Value) | -177.00M |
| Book Value Per Share | -7.06 |
| Working Capital | -36.21M |
Cash Flow
NKGen Biotech, Inc. Common Stock produced -20.87M in operating cash flow over the past twelve months.
| Operating Cash Flow | -20.87M |
| Capital Expenditures | N/A |
| Free Cash Flow | -20.87M |
| FCF Per Share | -0.83 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -127.46 |
| FCF Yield | -189.41 |
Scores
NKGen Biotech, Inc. Common Stock posts an Altman Z-Score of -26.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.38 |